Result card

  • TEC15: What information do patients outside the target group and the general public need on the use of FEMTELLE®, MammaPrint®, and Oncotype DX™?
English
No adaptation help available for this domain

What information do patients outside the target group and the general public need on the use of FEMTELLE®, MammaPrint®, and Oncotype DX™?

Authors: Pseudo169 Pseudo169, Pseudo90 Pseudo90, Pseudo154 Pseudo154, Pseudo98 Pseudo98

Internal reviewers: Patricia Harrington, Michelle O'Neill, Leonor Varela

A previous results card (RC-TEC14) was used to develop the present assessment element.

No additional information is required for patients or individuals outside the target group concerning  indications/contraindications, the procedure, and role of test in the diagnostic/therapeutic pathway. In the case of the test results, confidentiality is a major concern; no other people apart from the patient need to be informed about them.

Critical
Completely
Pseudo169 P et al. Result Card TEC15 In: Pseudo169 P et al. Description and technical characteristics of technology In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113